Elaine Moore writes,

With the increasing costs of specialized drugs, some insurance companies are refusing to pay for drugs prescribed for off-label conditions …

Health policy analysts caution that the benefits off-label drugs offer in conditions for which other drugs have failed will be seriously compromised by these new insurance regulations.

Furthermore, off-label drugs such as naltrexone, which is relatively inexpensive at less than $100 per month, would be put in the same (unapproved for payment) category as Genetech’s Avastin (bevacizumab), which typically costs $4,400 per month. Avastin is approved for lung and colorectal cancers, but not for brain tumors because of limited evidence validating efficacy despite promising results in patients.

About Cary Byrd

eDrugSearch founder, Cary Byrd, has been called an “e-health innovator” by MarketIntellNow, interviewed by top pharmaceutical industry journalists, invited to Matthew Holt’s Health 2.0 Conference and a Consumer Report's health summit, and highlighted on numerous health blogs.

eDrugSearch.com - Search. Compare. Save.

Leave a Reply

Join Our Free Newsletter

Please enter email id

Get a weekly dose of money-saving tips on your medications, drug side effects alerts, drug interaction warnings, free prescription coupons, late-breaking safety information and much, much more!

Share via
Copy link